Fig. 6. miR-206 reduces OS cell malignancy in vitro by targeting PAX3 and MET. miR-206 overexpressing OS cells were transfected with PAX3 or MET OE plasmids or treated with HGF before assay. (A) CCK-8 cell viability assay evaluating the overall cell growth in vitro. (B) Flow cytometry detection cell apoptosis. (C and D) Cell invasion and migration assay evaluating cell metastasis in vitro. (E) Representative results of cell migration and invasion assay. WT OS cells were used as a control for significance test. ^*p<0.01, ^†p<0.001. OS, osteosarcoma; OE, overexpressing; WT, wild-type, HGF, hepatocyte growth factor; NC, negative control.